Published 2 days ago • loading... • Updated 2 days ago

Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025

On Dec. 15, 2025, Caliway Biopharmaceuticals presented preclinical research on CBL-514 combined with tirzepatide at the 25th Annual Congress of the Taiwan Medical Association for the Study of Obesity held at National Taiwan University Hospital, New Taipei City.
Researchers argued that targeting adipose tissue biology alongside incretin-based therapies could improve fat distribution and weight loss durability, the scientific community at TMASO 2025 emphasized multi-mechanism strategies beyond appetite control.
In the animal study design, researchers included an observation period after incretin withdrawal, showing the combination produced greater weight and fat reductions than tirzepatide alone in diet-induced obese rat models.
Caliway said the findings warrant further clinical investigation of adipocyte-targeted mechanisms to complement incretin pipelines, while Dr. Tzu-Jung Chou stressed more research is needed and company disclosures noted forward-looking statements and associated risks.
Caliway Biopharmaceuticals, TWSE: 6919, aims to lead innovation as TMASO 2025 experts from Taiwan, Japan and Korea highlight shifts toward durable weight loss and visceral fat reduction.

Insights by Ground AI

27 Articles

keenesentinel.com

+26 Reposted by 26 other sources

Center

Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025

Caliway Biopharmaceuticals' preclinical research was highlighted at the 25th Annual Congress of the Taiwan Medical Association for the Study of Obesity, held in conjunction with the 9th Japan-Korea-Taiwan Symposium on Obesity.The animal study explored CBL-514 in combination with a dual…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year